Reed E - Search Results

1

ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients.

Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E. Dabholkar M, et al. Among authors: reed e. J Natl Cancer Inst. 1992 Oct 7;84(19):1512-7. doi: 10.1093/jnci/84.19.1512. J Natl Cancer Inst. 1992. PMID: 1433335

2

Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2.

Dabholkar MD, Berger MS, Vionnet JA, Egwuagu C, Silber JR, Yu JJ, Reed E. Dabholkar MD, et al. Among authors: reed e. Cancer Res. 1995 Mar 15;55(6):1261-6. Cancer Res. 1995. PMID: 7882319

3

Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells.

Parker RJ, Dabholkar MD, Lee KB, Bostick-Bruton F, Reed E. Parker RJ, et al. Among authors: reed e. J Natl Cancer Inst Monogr. 1993;(15):83-8. J Natl Cancer Inst Monogr. 1993. PMID: 7912534

4

Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.

Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Dabholkar M, et al. Among authors: reed e. J Clin Invest. 1994 Aug;94(2):703-8. doi: 10.1172/JCI117388. J Clin Invest. 1994. PMID: 8040325 Free PMC article.

5

Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies.

Reed E, Parker RJ, Gill I, Bicher A, Dabholkar M, Vionnet JA, Bostick-Bruton F, Tarone R, Muggia FM. Reed E, et al. Cancer Res. 1993 Aug 15;53(16):3694-9. Cancer Res. 1993. PMID: 8339278 Clinical Trial.

6

Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.

Parker RJ, Vionnet JA, Bostick-Bruton F, Reed E. Parker RJ, et al. Among authors: reed e. Cancer Res. 1993 Jan 15;53(2):242-7. Cancer Res. 1993. PMID: 8417816

7

A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues.

Yu JJ, Mu C, Lee KB, Okamoto A, Reed EL, Bostick-Bruton F, Mitchell KC, Reed E. Yu JJ, et al. Among authors: reed e, reed el. Mutat Res. 1997 Sep;382(1-2):13-20. doi: 10.1016/s1383-5726(97)00004-6. Mutat Res. 1997. PMID: 9360634

8

Effect of interleukin-1 alpha and tumour necrosis factor-alpha on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line.

Li Q, Bostick-Bruton F, Reed E. Li Q, et al. Among authors: reed e. Anticancer Res. 1998 Jul-Aug;18(4A):2283-7. Anticancer Res. 1998. PMID: 9703867

9

Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell lines.

Yu JJ, Mu C, Dabholkar M, Guo Y, Bostick-Bruton F, Reed E. Yu JJ, et al. Among authors: reed e. Int J Mol Med. 1998 Mar;1(3):617-20. doi: 10.3892/ijmm.1.3.617. Int J Mol Med. 1998. PMID: 9852275

10

Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.

Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F, Reed E. Yu JJ, et al. Among authors: reed e. Int J Oncol. 2000 Mar;16(3):555-60. doi: 10.3892/ijo.16.3.555. Int J Oncol. 2000. PMID: 10675489

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,331 results

Search Page

Filters